

PRELIMINARY PROGRAMME

● **Thursday, 10th June 2021** ●

12:00 – 12:10 Welcome to EuroCVP

12:10 - 12:15 Welcome Introduction to AACT and course objectives

AACT – PART 1

12:15 – 14:35 SESSION 1: HOW TO DESIGN AND RUN A CLINICAL TRIAL

12:15 – 12:40 An overview of the different aspects of clinical trials

12:50 – 13:15 Planning and running a clinical trial: site perspective

13:25 – 13:50 Traditional versus novel trial designing

14:00 – 14:25 Requirements from regulatory agencies and post marketing surveillance

14:35 – 14:50 Break

AACT – PART 2

14:50 – 16:45 SESSION 2: UPCOMING AND ONGOING CLINICAL TRIALS

14:50 – 15:15 Challenges of running a clinical trial during the pandemic

15:25 – 15:40 ACS / Antithrombotics

15:45 – 16:00 Lipidology

16:05 – 16:20 Diabetes

16:25 – 16:40 Heart failure

16:45 – 17:00 Break

Main Sessions – NEWS FROM OUR WORKING GROUP

17:00 – 18:00 SESSION 3: CHALLENGES IN CARDIOVASCULAR PHARMACOGENOMICS

17:00 – 17:20 Role of pharmacogenomics in cardiovascular medicine - Have we reached a consensus?

17:20 – 17:40 Pharmacogenomics and dyslipidaemia treatment – Statin-related myopathy

17:40 – 18:00 Discussion

18:00 – 19:00 SESSION 4: HOW TO MANAGE POST-OPERATIVE ANTI-THROMBOTIC THERAPY AFTER CARDIOVASCULAR SURGERY – GAPS IN EVIDENCE
Joint session with the ESC Working Group on Cardiovascular Surgery



18:00 – 18:20 **Pro:** Intensified antithrombotic regimen
18:20 – 18:40 **Con:** Relaxed antithrombotic regimen
18:40 – 19:00 **Discussion**

● **Friday, 11th June 2021** ●

AACT – PART 3

09:00 – 11:10 SESSION 5: CLINICAL TRIAL CATEGORIES AND STATISTICAL ISSUES

09:00 – 10:00 **WORKSHOP:** Randomized controlled trials
10:00 – 11:10 **WORKSHOP:** Observational studies and registries

11:10 – 11:25 **Break**

AACT – PART 4

11:25 – 13:15 SESSION 6: CLINICAL TRIAL CATEGORIES, STATISTICAL ISSUES AND INTERPRETATION

11:25 – 12:35 **WORKSHOP:** Systematic reviews and meta-analyses
12:35 – 13:15 **How to interpret clinical trial data – examples from clinical trials**
13:15 **AACT closing remarks**

13:15 – 14:00 **Lunch Break**

POP – PART 1

14:00 – 15:40 SESSION 7: PHARMACOTHERAPY IN THE ELDERLY - GENERAL ASPECTS

14:00 – 14:10 **Welcome** Introduction to POP and course objectives
14:10 – 14:30 **Polypharmacy** in the elderly
14:40 – 15:00 **Challenges** to cardiovascular pharmacotherapy imposed by aging and the added challenge of COVID-19
15:10 – 15:30 **HFpEF** – the central problem in symptomatic elderly patients with dyspnea?

15:40 – 16:00 **Break**

POP – PART 2

16:00 – 17:00 SESSION 8: MANAGEMENT OF HYPERTENSION IN OLDER PEOPLE

- 16:00 – 16:25 How to select anti-hypertensive agents in older patients – ACE and ARBs in the COVID-19 pandemic
16:25 – 16:40 Case presentation
16:40 – 17:00 Panel Discussion: The optimal management of hypertension in the elderly – especially during the pandemic

17:00 – 18:00 SESSION 9: DIURETICS IN THE ELDERLY

- 17:00 – 17:20 The problem of hypo- and hyperkalemia in older people
17:20 – 17:40 Diuretics in the treatment of hypertension: the drugs beyond the class
17:40 – 18:00 Panel Discussion: The optimal range of potassium

18:00 - 18:15 Break

Main Session – CARDIOVASCULAR PHARMACOTHERAPY AND COVID-19

18:15 – 19:45 SESSION 10: PHARMACOTHERAPY AND COVID-19
Joint Session with the ESC Working Group on Thrombosis



- 18:15 – 18:30 Statement of the ESC President-Elect – working post COVID-19
18:30 – 19:00 Keynote: Pharmacotherapy and COVID-19 – what can we learn from nationwide cohort studies
19:00 – 19:15 Antithrombotic Therapy in Patients with COVID-19
19:15 – 19:30 COVID-19 vaccination and thromboembolic events – is there a link?
19:30 – 19:45 Q&A and discussion

● **Saturday, 12th June 2021** ●

POP – PART 3

09:00 – 10:15 SESSION 11: GLUCOSE LOWERING DRUGS IN THE VERY ELDERLY

- 09:00 – 09:20 Role of newer antidiabetic drugs
09:20 – 09:40 How to achieve glycemic control safely
09:40 – 09:55 Case presentation
09:55 – 10:15 Expert Discussion: The optimal glycemic control in the elderly

10:15 – 11:15 SESSION 12: LIPID LOWERING DRUGS IN OLDER PEOPLE

10:15 – 10:35 Lipid lowering agent selection in the elderly

10:35 – 10:55 The future of lipid management: not only LDL-C

10:55 – 11:15 Panel Discussion: The use of intensified lipid lowering therapy in the elderly

11:15 - 11:30 Break

POP – PART 4

11:30 – 12:30 SESSION 13: ANTIPLATELET THERAPY IN THE ELDERLY

11:30 – 11:55 Guidelines & beyond

11:55 – 12:10 Case presentation

12:10 – 12:30 Panel Discussion: The use of intensified anti-platelet therapy in the elderly

12:30 – 13:45 SESSION 16: DOACS IN AF STROKE PREVENTION

12:30 – 12:50 The use of DOACs in older individuals

12:50 – 13:10 Triple Anti-Thrombotic Therapy in the elderly

13:10 – 13:25 Case presentation

13:25 – 13:45 Panel Discussion: Balancing the ischemic risk and risk of bleeding in the elderly

13:45 – 14:00 Closing remarks EuroCVP